Abbott (NYSE:ABT) filed three patent lawsuits against SiBionics and its distribution partner in Europe, JUVE-Patent reports. The lawsuits include patent infringement allegations centered around continuous glucose monitoring (CGM) devices, according to the report. Abbott filed them against China-based SiBionics and its sales partner Umedwings at the Unified Patent Court. SiBionics develops, manufactures and distributes CGM […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Dexcom stock slides despite Q1 beats, sales guidance increase
Dexcom shares took a hit after hours today on first-quarter results that came in ahead of the consensus forecast on Wall Street. Shares of DXCM dipped about 7% to $128.40 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day […]
Non-insulin, basal CGM use exceeds analysts’ expectations, Dexcom and Abbott to benefit
William Blair analyst Margaret Kaczor reported surprise at the increase in users of CGM within the non-insulin and basal insulin populations. Kaczor expects Dexcom and Abbott to benefit from the trend with their next-generation CGM offerings after meetings with both companies’ management. Both companies launched next-gen CGMs in recent years (Dexcom G7 and Abbott FreeStyle […]
10 new, innovative medical devices to watch for in 2024
By Senior Editor Danielle Kirsh and Associate Editor Sean Whooley Significant medical device launches are coming in 2024. Think pulsed field ablation, diabetes treatment tech, surgical robotics and more. Pulsed field ablation news took over at the end of 2023 and the start of 2024, with Medtronic and Boston Scientific garnering significant regulatory approvals. Surgical […]
Glucotrack expands CGM tech to spinal epidural space
Glucotrack (Nasdaq:GCTK) announced today that it plans to expand its glucose monitoring technology to measure glucose in the epidural space. Rutherford, New Jersey-based Glucotrack said CGM taking readings in the spinal epidural space could integrate with existing treatments for painful diabetic neuropathy (PDN). Specifically, Glucotrack sees spinal cord stimulation (SCS) technology as a potential integration […]
Dexcom, MD Revolution partner to integrate CGM into remote care platform
MD Revolution today announced a partnership with Dexcom to integrate CGM into its remote care management platform. Dexcom develops continuous glucose monitoring technology (CGM), including its latest-generation G7. The system pairs with smartphones — and now Apple Watches — to monitor the glucose levels of people with diabetes. MD Revolution’s remote care management platform integrates […]
Insulet applauds as UK begins artificial pancreas rollout
Insulet (Nasdaq:PODD) expressed its excitement today as a new diabetes initiative in the UK could bring artificial pancreas’ to many with diabetes. NHS England said tens of thousands of children and adults with type 1 diabetes in the country will receive an artificial pancreas. The initiative includes hybrid closed-loop automated insulin delivery systems like Insulet’s […]
Biolinq raises $58M to support intradermal glucose sensor
Biolinq announced today that it completed a $58 million financing to support the progression of its proprietary intradermal glucose sensor. Alpha Wave Ventures led the funding round. Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures also participated. Other contributors included existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, […]
Tandem Mobi automated insulin pump wins FDA nod for expanded pediatric use
Tandem Diabetes Care (Nasdaq:TNDM) announced that the FDA cleared its Mobi insulin pump for an expanded pediatric indication. The FDA approved Tandem’s 510(k) application for the use of Mobi in individuals two years of age and older. In an SEC filing dated April 1, the company said the decision came through on March 21. Previously, […]
Tandem Diabetes Care taps miniaturization and automation for its latest systems
Tandem Diabetes Care (Nasdaq:TNDM) EVP and Chief Strategy Officer Elizabeth Gasser didn’t exactly plan for the whirlwind past year or so. In the space of about two months, Tandem announced continuous glucose monitor (CGM) integration with the latest-generation technology from Dexcom and Abbott, launched its Tandem Source diabetes management platform and began the rollout of […]
Ypsomed sells pen needle, blood glucose monitor business to focus on insulin pump
Ypsomed announced today that it agreed to sell its pen needle and blood glucose monitoring (BGM) businesses to Medical Technology and Devices (MTD). With the transfer of these businesses, Ypsomed plans to focus its diabetes care business on insulin pumps. Specifically, it looks to the further development and marketing of the mylife Loop automated insulin […]